S&P 500 cuts losses as Nvidia climbs ahead of results
CAMBRIDGE/FRANKLIN - Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biotechnology company with a market capitalization of $826 million and impressive 109% stock return over the past year, announced Thursday that its anemia treatment Vafseo (vadadustat) is now broadly available across all Innovative Renal Care (IRC) clinics for dialysis patients with chronic kidney disease (CKD). InvestingPro analysis indicates the company maintains a Fair financial health rating despite current unprofitability.
IRC has implemented a standardized treatment protocol for Vafseo throughout its network of more than 230 dialysis centers across 28 states and Washington, D.C. The medication will be available to eligible patients who meet FDA-approved clinical criteria and have access through IRC’s care model. With revenue growth of 16.75% in the last twelve months, Akebia shows promising commercial momentum. For deeper insights into Akebia’s growth potential, InvestingPro subscribers can access 10 additional exclusive ProTips and comprehensive financial metrics.
Vafseo, approved by the FDA in March 2024 for treating anemia in adults who have been on dialysis for at least three months, became commercially available in the U.S. in January 2025.
"IRC is focused on delivering patient-centered care through strong partnerships that support our mission of delivering more tomorrows to patients," said Dr. Geoffrey Walker, Chief Medical Officer at Innovative Renal Care, according to the company’s press release.
Nicholas Grund, Senior Vice President and Chief Commercial Officer at Akebia, stated that Vafseo is now accessible to over 55,000 patients through dialysis provider protocols. The company expects to expand total access to more than 275,000 patients by the end of the fourth quarter. Wall Street analysts appear optimistic about this expansion, with price targets ranging from $6 to $10 per share, suggesting significant potential upside from the current trading price of $3.12. Detailed analyst coverage and Fair Value assessments are available through InvestingPro’s comprehensive research reports.
Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates endogenous production of erythropoietin to manage anemia. The medication is currently approved in 37 countries.
The most common adverse reactions reported in clinical trials were hypertension and diarrhea. The FDA approval includes a boxed warning about increased risks of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
The announcement was made in a joint press release from Akebia Therapeutics and Innovative Renal Care.
In other recent news, Akebia Therapeutics reported its financial results for the second quarter of 2025, showing a mixed performance that has caught the attention of investors. The company posted zero earnings per share, which fell short of the anticipated $0.02 loss per share. However, Akebia exceeded revenue expectations, reporting $62.5 million compared to the forecasted $47.64 million. Despite the revenue beat, the earnings miss has raised concerns among investors. These developments have led to a significant reaction in the market, reflecting uncertainty about Akebia’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.